Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN10018 + RNK08954
- Development stage
- Phase 2
- Lead developer
- InxMed (Shanghai) Co., Ltd.
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IN10018 + RNK08954 is a combination therapy being developed by InxMed (Shanghai) Co., Ltd. for the treatment of KRASG12D mutation-positive advanced solid tumors. IN10018 (ifebemtinib) is a potent and selective oral small molecule inhibitor of focal adhesion kinase (FAK), which plays a critical role in modulating the tumor microenvironment and overcoming resistance to various targeted therapies. RNK08954 is a targeted protein degrader specifically designed to target and degrade the KRASG12D mutant protein. This combination aims to synergistically inhibit oncogenic signaling and improve clinical outcomes in patients with pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer harboring the KRASG12D mutation.
- Other names
- ifebemtinib + RNK08954
02
Targets
FAK (Focal adhesion kinase)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on IN10018 + RNK08954.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN10018 + RNK08954.